Oct 2, 2018 Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma Learn More
Sep 27, 2018 Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference Learn More
Sep 25, 2018 Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma Learn More